Regeneron advances first program from Abcellera collaboration into further preclinical development
Nov. 3, 2022
Regeneron Pharmaceuticals Inc. has elected to exercise its right to advance a therapeutic antibody candidate, discovered in partnership with Abcellera Biologics Inc. as part of a multitarget collaboration between the companies, into further preclinical development.